Prof. Dr. Annette Kopp-Schneider

Background

• Diploma in Mathematics, RWTH Aachen, Germany, 1984
• Dr. rer. nat., Mathematics, RWTH Aachen, Germany, 1987
• Habilitation, Medical Biometry, University Heidelberg, 1997

Areas of Work

• Clinical trials for precision oncology
• Dose response modelling
• Biological based mechanistic modelling of cell systems

Selected Publications

van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, ... Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM, Witt O. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021 Nov;11(11):2764-2779. doi: 10.1158/2159-8290.CD-21-0094.

Wiesenfarth M, Reinke A, Landman BA, Eisenmann M, Saiz LA, Cardoso MJ, Maier-Hein L, Kopp-Schneider A. (2021) Methods and open-source toolkit for analyzing and visualizing challenge results. Sci Rep. 11(1):2369. doi: 10.1038/s41598-021-82017-6.

Zocholl D, Wiesenfarth M, Rauch G, Kopp-Schneider A. On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults. J Biopharm Stat. 2021 Online ahead of print. doi: 10.1080/10543406.2021.2011905.

Maier-Hein L, Reinke A, Kozubek M, Martel AL, Arbel T, Eisenmann M, Hanbury A, Jannin P, Müller H, Onogur S, Saez-Rodriguez J, van Ginneken B, Kopp-Schneider A, Landman BA. (2020) BIAS: Transparent reporting of biomedical image analysis challenges. Med Image Anal. 66:101796. doi: 10.1016/j.media.2020.101796.

Kopp-Schneider A, Calderazzo S, Wiesenfarth M. (2020) Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control. Biom J.;62(2):361-374..doi: 10.1002/bimj.201800395

Calderazzo S, Tavel D, Zurich MG, Kopp-Schneider A. (2019) Model-based estimation of lowest observed effect concentration from replicate experiments to identify potential biomarkers of in vitro neurotoxicity. Arch Toxicol. 93(9):2635-2644.. doi: 10.1007/s00204-019-02520-8

Maier-Hein L, Eisenmann M, ..., Jannin P, Kopp-Schneider A. Why rankings of biomedical image analysis competitions should be interpreted with care. Nat Commun. 2018 Dec 6;9(1):5217. doi: 10.1038/s41467-018-07619-7

Kopp-Schneider A, Wiesenfarth M, Witt R, Edelmann D, Witt O, Abel U. (2019) Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach. Biom J. 61: 488-502. doi: 10.1002/bimj.201700209

Holland-Letz T, Gunkel N, Amtmann E, Kopp-Schneider A. (2018) Parametric modelling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology. J Biopharmaceut Stat 28(4):763-777. doi: 10.1080/10543406.2017.1397005

Habermehl C, Benner A, Kopp-Schneider A. (2018) Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction. Biom J. 60(2):275-287. doi: 10.1002/bimj.201600226

Holland-Letz T, Kopp-Schneider A. (2018) Optimal experimental designs for estimating the drug combination index in toxicology. Computational Statistics and Data Analysis 117: 182–193. doi: 10.1016/j.csda.2017.08.006

Jiang X., Kopp-Schneider A. (2014) Summarizing EC50 estimates from multiple dose-response experiments: a comparison of a meta-analysis strategy to a mixed-effects model approach. Biom J. 56(3), 493-512. doi: 10.1002/bimj.201300123